LGC Opens New Oxford Facility
LGC (Teddington, UK) has opened a state-of-the-art facility at the Oxford Technology Park (OTP), Oxford, UK. The laboratory was officially opened by Dame Sarah Gilbert DBE and Teresa Lambe OBE, creators of the Oxford AstraZeneca COVID-19 vaccine.
The site will serve as the new home of The Native Antigen Company (TNAC), part of LGC Clinical Diagnostics, and as the host site of an advanced workflow applications laboratory for LGC Biosearch Technologies. It will offer TNAC significantly expanded manufacturing capacity for the production of infectious disease reagents, antibodies, and assays.
“We are delighted to be opening this new, purpose-built facility in Oxford Technology Park, which both expands our manufacturing capacity and provides an enhanced platform,” said Euan O’Sullivan, President and Chief Executive Officer, LGC.
“Our larger manufacturing capacity, greater development of new products, and larger scale production will prove vital for our customers, as it gives us greater ability to move into new areas such as BSL-3 or GMP production,” continued O’Sullivan.
Dame Sarah Gilbert DBE, Professor of Vaccinology at the University of Oxford, said, “I am so pleased to be able to officially open this exciting facility. Following on from the pandemic, I know full well the importance of producing infectious disease reagents, antibodies, and assays, and research into diagnostic tests and treatments—and the work that will be carried out here will continue to impress.”
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
